NCT05652673 is a NA clinical trial of nivolumab in Melanoma Stage IV, sponsored by Erasmus Medical Center.

Who is sponsoring NCT05652673?

NCT05652673 is sponsored by Erasmus Medical Center.

What drugs are being tested in NCT05652673?

Interventions in NCT05652673: nivolumab.

What condition does NCT05652673 study?

NCT05652673 studies Melanoma Stage IV, Melanoma Stage III, Immunotherapy, Toxicity, Drug.

Is NCT05652673 still recruiting?

NCT05652673 is currently recruiting now. Last updated 28 February 2025.

Last reviewed 2025-02-28 · How we verify

NCT05652673

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Recruiting now NA Last updated 28 February 2025

What this trial tests

NA trial testing nivolumab in Melanoma Stage IV in 80 participants. Currently enrolling.

Timeline

1 February 2023

Primary endpoint
1 December 2025

1 December 2029

Quick facts

Lead sponsor	Erasmus Medical Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 February 2023
Primary completion	1 December 2025
Estimated completion	1 December 2029
Sites	1 location across Netherlands

Drugs / interventions tested

nivolumab (nivolumab) — full drug profile →

Conditions studied

Melanoma Stage IV — all drugs for Melanoma Stage IV →
Melanoma Stage III — all drugs for Melanoma Stage III →
Immunotherapy — all drugs for Immunotherapy →
Toxicity, Drug — all drugs for Toxicity, Drug →

Sponsor

Erasmus Medical Center

Who can join

18 and older, any sex, with Melanoma Stage IV or Melanoma Stage III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
Chatziioannou E, Leiter U, Thomas I, Keim U, et al · · 2023 · cited 15× · PMID 37142875 · DOI 10.1007/s40257-023-00775-7
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC, van Dijk B, de Joode K, Aarts MJB, et al · · 2024 · cited 6× · PMID 38783238 · DOI 10.1186/s12885-024-12336-0
Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis.
Mayer KE, Warburton L, Zaremba A, Preis S, et al · · 2025 · cited 4× · PMID 40181695 · DOI 10.1111/jdv.20672
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?
Kumar V, Wei XX. · · 2023 · cited 3× · PMID 38993185 · DOI 10.3233/blc-230039
ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the Literature.
Rota S, Sciortino C, Damian S, Duca M, et al · · 2025 · cited 1× · PMID 41200780 · DOI 10.1002/cnr2.70397
Waiting for ASCO to "Walk the Walk".
Fojo T. · · 2023 · cited 1× · PMID 37774404 · DOI 10.1093/oncolo/oyad256
Dose optimization of immune checkpoint inhibitors for gastrointestinal malignancies.
Alsina M, Beunza-Sola M, Fernández-Montes A, Padrón-Rodriguez B, et al · · 2026 · PMID 42180266 · DOI 10.1016/j.esmogo.2026.100338
Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events.
Triggiano G, Pezzicoli G, Tucci M. · · 2025 · PMID 40427544 · DOI 10.3390/biom15050651

Verify or expand the search:

Other trials of nivolumab

Trials testing the same drug.

NCT07176975 — A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanes · Phase 1 · not yet recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT06410534 — A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primar · Phase 2 · withdrawn
NCT06421311 — Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France · terminated
NCT05743270 — Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN · Phase 2 · withdrawn

Other recruiting trials for Melanoma Stage IV

Currently open trials in the same condition.

NCT06319196 — Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma · Phase 2 · recruiting
NCT06204991 — To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma · Phase 1 · recruiting
NCT06444815 — A Study of VET3-TGI in Patients With Solid Tumors · Phase 1 · recruiting
NCT06508775 — Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies · NA · recruiting
NCT05655312 — MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma · Phase 1, PHASE2 · recruiting

Other Erasmus Medical Center trials

Trials by the same sponsor.

NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05652673 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
Last refreshed: 28 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05652673.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing